BioBullets: The Great Dispersion
Mike and Ben talk about Scott Galloway's theory of the Great Dispersion - the impact of COVID on business models…
BioBullets: The Aduhelm FDA approval controversy
This podcast accompanies Horizon 3 Biotech's BioBullets email for the 13th August 2021
Introduction to Horizon 3
A chance to meet with Mike, Horizon 3's Executive Chairman, and Matt, the Chief Investment Officer, as they talk about…
Topical investment strategies in biotech
Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt will be joined by Horizon 3 Biotech…
Matt talks to Dimerix & Crucible Investments
Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. Matt & Scott Power speak to Dr Nina Webster from…
Healthcare investment and the outlook for 2021
Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt will be joined by Investment Analyst…
Accessing US markets – Nasdaq and FDA approval
Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. In this episode Matt will be joined by Opthea CEO &…
Horizon 3 Biotech Fund and what drives investment decisions
Hosted by Horizon 3 Biotech Chief Investment Officer Matt McNamara. Matt & Scott Power, Investment Committee at Horizon 3 Biotech,…